Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
Nat Med
    October 2026
  1. LONG GV, Pires da Silva I, Perry KA, Romano J, et al
    Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
    Nat Med. 2026 Oct 1. doi: 10.1038/s41591-026-04677.
    >> Share

    July 2026
  2. CARLINO MS, Kapiteijn E, Piperno-Neumann S, Sullivan RJ, et al
    An anti-PMEL antibody-drug conjugate with a G(q/1)(1) inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.
    Nat Med. 2026 Jul 13. doi: 10.1038/s41591-026-04518.
    >> Share

    January 2026
  3. DUTTAGUPTA S, Messaoudene M, Hunter S, Desilets A, et al
    Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.
    Nat Med. 2026 Jan 28. doi: 10.1038/s41591-025-04186.
    >> Share

  4. HOEIJMAKERS LL, Dimitriadis P, Wijnen SCMA, Reijers ILM, et al
    Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.
    Nat Med. 2026 Jan 28. doi: 10.1038/s41591-025-04158.
    >> Share

    October 2025
  5. LONG GV, Garnett-Benson C, Dolfi S, Ascierto PA, et al
    Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
    Nat Med. 2025 Oct 18. doi: 10.1038/s41591-025-04032.
    >> Share

    September 2025
  6. LONG GV, Nair N, Marbach D, Scolyer RA, et al
    Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.
    Nat Med. 2025 Sep 24. doi: 10.1038/s41591-025-03967.
    >> Share

    August 2025
  7. KENDRA KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, et al
    Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
    Nat Med. 2025 Aug 26. doi: 10.1038/s41591-025-03975.
    >> Share

  8. KENDRA KL, Bellasea SL, Eroglu Z, Hu-Lieskovan S, et al
    Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
    Nat Med. 2025 Aug 14. doi: 10.1038/s41591-025-03875.
    >> Share

  9. BORGERS JSW, Lenkala D, Kohler V, Jackson EK, et al
    Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.
    Nat Med. 2025 Aug 4. doi: 10.1038/s41591-025-03896.
    >> Share

  10. MIGLINO N, Toussaint NC, Ring A, Bonilla X, et al
    Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma.
    Nat Med. 2025 Aug 1. doi: 10.1038/s41591-025-03904.
    >> Share

  11. YAN S, Yu Z, Primiero C, Vico-Alonso C, et al
    A multimodal vision foundation model for clinical dermatology.
    Nat Med. 2025;31:2691-2702.
    >> Share

    July 2025
  12. MILOTAY G, Little M, Watson RA, Muldoon D, et al
    CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.
    Nat Med. 2025;31:2350-2364.
    >> Share

  13. WERMKE M, Araujo DM, Chatterjee M, Tsimberidou AM, et al
    Autologous T cell therapy for PRAME(+) advanced solid tumors in HLA-A*02(+) patients: a phase 1 trial.
    Nat Med. 2025;31:2365-2374.
    >> Share

    June 2025
  14. MONSON KR, Ferguson R, Handzlik JE, Morales L, et al
    Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.
    Nat Med. 2025 Jun 5. doi: 10.1038/s41591-025-03699.
    >> Share

    May 2025
  15. MIGLINO N, Toussaint NC, Ring A, Bonilla X, et al
    Feasibility of multiomics tumor profiling for guiding treatment of melanoma.
    Nat Med. 2025 May 27. doi: 10.1038/s41591-025-03715.
    >> Share

    January 2025
  16. DUMMER R, Robert C, Scolyer RA, Taube JM, et al
    Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.
    Nat Med. 2025 Jan 7. doi: 10.1038/s41591-024-03411.
    >> Share

  17. BORGERS JSW, Lenkala D, Kohler V, Jackson EK, et al
    Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.
    Nat Med. 2025 Jan 3. doi: 10.1038/s41591-024-03418.
    >> Share

    June 2024
  18. LONG GV, Carlino MS, Au-Yeung G, Spillane AJ, et al
    Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.
    Nat Med. 2024 Jun 21. doi: 10.1038/s41591-024-03077.
    >> Share

  19. O'LEARY K
    Neoadjuvant immunotherapy a new standard of care for melanoma.
    Nat Med. 2024 Jun 17. doi: 10.1038/d41591-024-00045.
    >> Share

    February 2024
  20. BJORK JR, Bolte LA, Maltez Thomas A, Lee KA, et al
    Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.
    Nat Med. 2024 Feb 16. doi: 10.1038/s41591-024-02803.
    >> Share

    January 2024
  21. O'LEARY K
    Personalized mRNA vaccine boosts melanoma immunotherapy.
    Nat Med. 2024 Jan 25. doi: 10.1038/d41591-024-00006.
    >> Share

  22. KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al
    Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2024 Jan 4. doi: 10.1038/s41591-023-02775.
    >> Share

    November 2023
  23. FRATERMAN I, Reijers ILM, Dimitriadis P, Broeks A, et al
    Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.
    Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02631.
    >> Share

  24. ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al
    Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
    Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02650.
    >> Share

  25. KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al
    Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02661.
    >> Share

    October 2023
  26. KIRKWOOD J, Del Vecchio M, Weber J, Hoeller C, et al
    Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
    Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02583.
    >> Share

    August 2023
  27. VANDERWALDE A, Bellasea SL, Kendra KL, Khushalani NI, et al
    Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
    Nat Med. 2023 Aug 17. doi: 10.1038/s41591-023-02498.
    >> Share

  28. CARVALHO T
    Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial.
    Nat Med. 2023 Aug 16. doi: 10.1038/d41591-023-00072.
    >> Share

  29. BARATA C, Rotemberg V, Codella NCF, Tschandl P, et al
    A reinforcement learning model for AI-based decision support in skin cancer.
    Nat Med. 2023;29:1941-1946.
    >> Share

    July 2023
  30. ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al
    Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
    Nat Med. 2023 Jul 6. doi: 10.1038/s41591-023-02453.
    >> Share

  31. BRASTIANOS PK, Kim AE, Giobbie-Hurder A, Lee EQ, et al
    Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
    Nat Med. 2023;29:1728-1737.
    >> Share

    May 2023
  32. GARBE C, Dummer R, Amaral T, Amaria RN, et al
    Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
    Nat Med. 2023 May 16. doi: 10.1038/s41591-023-02336.
    >> Share

    April 2023
  33. LIU S, Dharanipragada P, Lomeli SH, Wang Y, et al
    Multi-organ landscape of therapy-resistant melanoma.
    Nat Med. 2023 Apr 27. doi: 10.1038/s41591-023-02304.
    >> Share

  34. GLITZA OLIVA IC, Ferguson SD, Bassett R Jr, Foster AP, et al
    Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
    Nat Med. 2023;29:898-905.
    >> Share

    March 2023
  35. O'LEARY K
    Earlier appears better for immunotherapy in melanoma.
    Nat Med. 2023 Mar 16. doi: 10.1038/d41591-023-00028.
    >> Share

  36. CASCONE T, Leung CH, Weissferdt A, Pataer A, et al
    Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-022-02189.
    >> Share

    February 2023
  37. TIAN J, Chen JH, Chao SX, Pelka K, et al
    Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial.
    Nat Med. 2023;29:458-466.
    >> Share

  38. NIKNAFS N, Balan A, Cherry C, Hummelink K, et al
    Persistent mutation burden drives sustained anti-tumor immune responses.
    Nat Med. 2023;29:440-449.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016